Systemic Treatment for Gynecological Cancer Patients Undergoing Hemodialysis

Abstract

Gynecological cancer poses a serious threat to women’s health. Chemotherapy-based systemic therapy plays a crucial role in the treatment of gynecological cancers. Many systemic therapeutic drugs are metabolized in the kidneys. Therefore, normal renal function is a prerequisite for gynecological tumor patients to complete the full course of systematic treatment and provide a guarantee for achieving an ideal prognosis. Chronic kidney disease often places restrictions on systematic treatment to different extents, such as influencing drug pharmacokinetics, increasing drug toxicity, and the risk of adverse drug reactions. Unfortunately, women undergoing renal replacement have a higher risk of developing gynecological cancers. This article summarizes the current knowledge on systemic treatment drugs for patients with gynecological cancer undergoing dialysis. We discuss the optimal choice of the systematic therapeutic protocol, administration of form and dosage, and window of chemotherapy during hemodialysis sessions to ensure both effectiveness and safety in gynecological cancer patients.

Keywords:

• hemodialysis
• renal insufficiency
• systemic treatment
• gynecological cancer

Disclosure

The authors report no conflicts of interest in this work.

Additional information

Funding

This work was funded by the Natural Science Research Project of Jiading District, Shanghai (grant number JDKW-2022-0036) and the National Natural Science Foundation of China (grant number 82201846, 81974454).